Search

Your search keyword '"Haag, Friedrich"' showing total 5 results
Start Over Author "Haag, Friedrich" Journal scientific reports
5 results on '"Haag, Friedrich"'

1. Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia

Author

Rissiek, Björn, primary, Menzel, Stephan, additional, Leutert, Mario, additional, Cordes, Maike, additional, Behr, Sarah, additional, Jank, Larissa, additional, Ludewig, Peter, additional, Gelderblom, Mathias, additional, Rissiek, Anne, additional, Adriouch, Sahil, additional, Haag, Friedrich, additional, Hottiger, Michael O., additional, Koch-Nolte, Friedrich, additional, and Magnus, Tim, additional

Published
2017
Full Text
View/download PDF

2. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

Author

Fumey, William, primary, Koenigsdorf, Julia, additional, Kunick, Valentin, additional, Menzel, Stephan, additional, Schütze, Kerstin, additional, Unger, Mandy, additional, Schriewer, Levin, additional, Haag, Friedrich, additional, Adam, Gerhard, additional, Oberle, Anna, additional, Binder, Mascha, additional, Fliegert, Ralf, additional, Guse, Andreas, additional, Zhao, Yong Juan, additional, Cheung Lee, Hon, additional, Malavasi, Fabio, additional, Goldbaum, Fernando, additional, van Hegelsom, Rob, additional, Stortelers, Catelijne, additional, Bannas, Peter, additional, and Koch-Nolte, Friedrich, additional

Published
2017
Full Text
View/download PDF

3. Tuning IL-2 signaling by ADP-ribosylation of CD25

Author

Teege, Sophie, primary, Hann, Alexander, additional, Miksiewicz, Maria, additional, MacMillan, Cary, additional, Rissiek, Björn, additional, Buck, Friedrich, additional, Menzel, Stephan, additional, Nissen, Marion, additional, Bannas, Peter, additional, Haag, Friedrich, additional, Boyer, Olivier, additional, Seman, Michel, additional, Adriouch, Sahil, additional, and Koch-Nolte, Friedrich, additional

Published
2015
Full Text
View/download PDF

4. Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT

Author

Unger, Mandy, primary, Eichhoff, Anna Marei, additional, Schumacher, Lucas, additional, Strysio, Moritz, additional, Menzel, Stephan, additional, Schwan, Carsten, additional, Alzogaray, Vanina, additional, Zylberman, Vanesa, additional, Seman, Michel, additional, Brandner, Johanna, additional, Rohde, Holger, additional, Zhu, Kai, additional, Haag, Friedrich, additional, Mittrücker, Hans-Willi, additional, Goldbaum, Fernando, additional, Aktories, Klaus, additional, and Koch-Nolte, Friedrich, additional

Published
2015
Full Text
View/download PDF

5. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38 + tumors in mouse models in vivo.

Author

Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao YJ, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, and Koch-Nolte F

Subjects
ADP-ribosyl Cyclase 1 immunology, Animals, Camelids, New World, Cell Line, Tumor, Cell Surface Display Techniques, Disease Models, Animal, Epitopes immunology, Fluorescent Dyes, Humans, Membrane Glycoproteins immunology, Mice, Mice, Nude, Multiple Myeloma pathology, Xenograft Model Antitumor Assays, ADP-ribosyl Cyclase 1 metabolism, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Membrane Glycoproteins metabolism, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Single-Domain Antibodies immunology
Abstract

The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple myeloma. Our aim was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for hematological malignancies. We successfully identified 22 CD38-specific nanobody families using phage display technology from immunized llamas. Crossblockade analyses and in-tandem epitope binning revealed that the nanobodies recognize three different non-overlapping epitopes, with four nanobody families binding complementary to daratumumab. Three nanobody families inhibit the enzymatic activity of CD38 in vitro, while two others were found to act as enhancers. In vivo, fluorochrome-conjugated CD38 nanobodies efficiently reach CD38 expressing tumors in a rodent model within 2 hours after intravenous injection, thereby allowing for convenient same day in vivo tumor imaging. These nanobodies represent highly specific tools for modulating the enzymatic activity of CD38 and for diagnostic monitoring CD38-expressing tumors.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results